Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology

Atherosclerosis

Volumn 241, Issue 1, 2015, Pages 169-175

  De Backer, Guy ^a   Besseling, Joost ^b   Chapman, John ^c   Hovingh, G Kees ^b   Kastelein, John J P ^b   Kotseva, Kornelia ^d   Ray, Kausik ^e   Reiner, Željko ^f   Wood, David ^d   De Bacquer, Dirk ^a  

^a GHENT UNIVERSITY   (Belgium)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c SORBONNE UNIVERSITÉ   (France)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^f KBC Zagreb   (Croatia)

Author keywords

Coronary heart disease; Familial hypercholesterolaemia; Prevalence; Risk factors

Indexed keywords

EZETIMIBE; GLYCEROL 3 PHOSPHATE DEHYDROGENASE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY HEIGHT; BODY MASS; BODY WEIGHT; CARDIAC PATIENT; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; WAIST CIRCUMFERENCE; AGE; AGE DISTRIBUTION; CLINICAL TRIAL; COMORBIDITY; CORONARY DISEASE; CROSS-SECTIONAL STUDY; EUROPE; GENETIC PREDISPOSITION; GENETICS; HEALTH SURVEY; HYPERLIPOPROTEINEMIA TYPE II; LIFESTYLE; MIDDLE AGED; MULTICENTER STUDY; PHENOTYPE; SEX DIFFERENCE; SEX RATIO; TREATMENT OUTCOME;

AGE DISTRIBUTION; AGE FACTORS; AGED; COMORBIDITY; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; EUROPE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEALTH SURVEYS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIFE STYLE; MALE; MIDDLE AGED; PHENOTYPE; PREVALENCE; RISK FACTORS; SEX DISTRIBUTION; SEX FACTORS; TREATMENT OUTCOME;

EID: 84929413403     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.04.809     Document Type: Article

References (27)

1. Goldstein J.L., Schrott H.G., Hazzard W.R., Bierman E.L., Motulsky A.G. Hyperlipidemia in coronary heart disease II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J.Clin. Invest. 1973, 52:1544-1568.
2. Cuchel M., Bruckert E., Ginsberg H.N., et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the European Atherosclerosis Society. Eur. Heart J. 2014 Aug 21, 35(32):2146-2157.
3. Reiner Ž. Impact of early evidence of atherosclerotic changes on early treatment in children with familial hypercholesterolemia. Circ. Res. 2014, 114:233-235.
4. Sjouke B., Kusters D.M., Kindt I., Besseling J., Defesche J.C., Sijbrands E.J., Roeters van Lennep J.E., Stalenhoef A.F., Wiegman A., de Graaf J., Fouchier S.W., Kastelein J.J., Hovingh G.K. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur. Heart. J. 2015, 36:560-565.
5. Nordestgaard B.J., Chapman M.J., Humphries S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur. Heart J. 2013, 34:3478-3490.
6. Scientific Steering Committee on behalf of the Simon Broome Register Group Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991, 303:893-896.
7. WHO Familial Hypercholesterolemia Consultation Group Familial Hypercholesterolemia. Report of a WHO Consultation 1998, WHO, Paris, Report n: WHO/HGN/FH/CONS/98.7.
8. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004, 173:55-68.
9. Reiner Z., Catapano A.L., De Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and theEuropean Atherosclerosis Society (EAS). Eur. Heart J. 2011, 32(14):1769-1818.
10. Kotseva K., Wood D., De Bacquer D., De Backer G., Ryden L., Jennings C., Gyberg V., on behalf of the EUROASPIRE Investigators EUROASPIRE IV: a European society of cardiology survey on the lifestyle, risk factor and therapeutic management in coronary patients from 24 European countries. Eur. J. Prev. Cardiol. 2015, 10.1177/2047487315569401.
11. Besseling J., Kindt I., Hof M., et al. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers. Atherosclerosis 2014, 233:219-223.
12. Marks D., Thorogood M., Neil H.A., Humphries S.E. Areview on the diagnosis, natural history and treatment of familial hypercholesterlaemia. Atherosclerosis 2003, 168:1-14. 12.
13. Hopkins P.N., Toth P.P., Ballantyne C.M., Rader D.J. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the national lipid association expert panel on familial hypercholesterolemia. J.Clin. Lipidol. 2011, 5:S9-S17.
14. Neil H.A., Hammond T., Huxley R., Matthews D.R., Humphries S.E. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ 2000, 321:148.
15. Benn M., Watts G.F., Tybjaerg-Hansen A., Nordestgaard B.G. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease and cholesterol-lowering medication. J.Clin. Endocrinol. Metab. 2012, 97:3956-3964.
16. de Ferranti S., Rodday A.M., Mendelson M., Wong J.B., Leslie L.K., Sheldrick R.C. What is the prevalence of familial hypercholesterolemia in the US?. Analysis NHANES 1999-2012, AHA Scientific Sessions 2014, nov 16th abstract 2261.
17. Shi Z., Yuan B., Zhao D., et al. Familial hypercholesterolemia in China: prevalence and evidence of underdetection and undertreatment in a community population. Int. J. Cardiol. 2014, http://dx.doi.org/10.1016/j.ijcard.2014.04.165.
18. Dorsch M.F., Lawrance R.A., Durham N.P., Hall A.S. Familial hypercholesterolaemia is underdiagnosed after AMI. BMJ 2001, 322:111.
19. Austin M.A., Hutter C.M., Zimmern R.L., Humphries S.E. Familial hypercholesterolemia and coronary heart disease: a huge association review. Am. J. Epidemiol. 2004, 160:421-429.
20. Do R., Stitziel N.O., Won H., Jørgensen A.B., Duga S., Angelica Merlini P., Kiezun A., Farrall M., Goel A., Zuk O., Guella I., Asselta R., Lange L.A., Peloso G.M., Auer P.L., NHLBI Exome Sequencing Project, Girelli D., Martinelli N., Farlow D.N., DePristo M.A., Roberts R., Stewart A.F., Saleheen D., Danesh J., Epstein S.E., Sivapalaratnam S., Kees Hovingh G., Kastelein J.J., Samani N.J., Schunkert H., Erdmann J., Shah S.H., Kraus W.E., Davies R., Nikpay M., Johansen C.T., Wang J., Hegele R.A., Hechter E., Marz W., Kleber M.E., Huang J., Johnson A.D., Li M., Burke G.L., Gross M., Liu Y., Assimes T.L., Heiss G., Lange E.M., Folsom A.R., Taylor H.A., Olivieri O., Hamsten A., Clarke R., Reilly D.F., Yin W., Rivas M.A., Donnelly P., Rossouw J.E., Psaty B.M., Herrington D.M., Wilson J.G., Rich S.S., Bamshad M.J., Tracy R.P., Adrienne Cupples L., Rader D.J., Reilly M.P., Spertus J.A., Cresci S., Hartiala J., Wilson Tang W.H., Hazen S.L., Allayee H., Reiner A.P., Carlson C.S., Kooperberg C., Jackson R.D., Boerwinkle E., Lander E.S., Schwartz S.M., Siscovick D.S., McPherson R., Tybjaerg-Hansen A., Abecasis G.R., Watkins H., Nickerson D.A., Ardissino D., Sunyaev S.R., O'Donnell C.J., Altshuler D., Gabriel S., Kathiresan S. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 2014 Dec 10, 10.1038/nature13917.
21. Damgaard D., Larsen M.L., Nissen P.H., et al. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis 2005, 180:155-160.
22. Humphries S.E., Galton D., Nicholls P. Genetic testing for familial hypercholesterolaemia: practical and ethical issues. QJM 1997, 90:169-181.
23. Stone N.J., Robinson J.G., Lichtenstein A.H., Bairey Merz C.N., Blum C.B., Eckel R.H., Goldberg A.C., Gordon D., Levy D., Lloyd-Jones D.M., McBride P., Schwartz J.S., Shero S.T., Smith S.C., Watson K., Wilson P.W., Eddleman K.M., Jarrett N.M., LaBresh K., Nevo L., Wnek J., Anderson J.L., Halperin J.L., Albert N.M., Bozkurt B., Brindis R.G., Curtis L.H., DeMets D., Hochman J.S., Kovacs R.J., Ohman E.M., Pressler S.J., Sellke F.W., Shen W.K., Smith S.C., Tomaselli G.F. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 129:S1-S45.
24. Reiner Ž. Acomparison of European and US guidelines for familial hypercholesterolaemia. Curr. Opin. Lipidol. 2014, 25:472-475.
25. Nordestgaard B.G., Chapman M.J., Ray K., Borén J., Andreotti F., Watts G.F., Ginsberg H., Amarenco P., Catapano C., Descamps O.S., Fisher E., Kovanen P.T., Kuivenhoven J.A., Lesnik P., Masana L., Reiner Z., Taskinen M.R., Tokgözoglu L., Tybjærg-Hansen A. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 2010, 31(23):2844-2853.
26. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003, 326:1423-1427.
27. Reiner Ž Resistance and intolerance to statins. Nutr. Metab. Cardiovasc. Dis. 2014, 24:1057-1066.